Study details
Enrolling now
A Phase 1 Trial of Orca-Q
Orca Biosystems, Inc.
NCT IDNCT03802695ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
300
Study length
about 8.7 years
Ages
12–78
Locations
9 sites in CA, FL, GA +4
What this study is about
This trial is testing the safety and how well Orca-Q works in people who are getting a bone marrow transplant for leukemia, mixed phenotype acute leukemia, or myelodysplastic syndromes. The treatment type is biological medication.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive OrcaGraft (Orca-Q)
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: Disease-free Survival (DFS) through Day +365, GVHD-free and Relapse-free Survival (GRFS) through Day +365, Overall Survival through Day +365
Body systems
Oncology